Using losartan to enhance cystic fibrosis treatment response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of losartan on patients with cystic fibrosis who are already receiving modulator therapy. It is a randomized, placebo-controlled study that will last for twelve weeks, during which participants will either receive losartan or a placebo. The primary outcome measure will be changes in sweat chloride levels, which serve as an indicator of CFTR channel function. The goal is to determine if losartan can improve the efficacy of existing treatments for cystic fibrosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Established diagnosis of cystic fibrosis
* Age 12 years and older
* Stable use of elexacaftor/tezacaftor/ivacaftor for 90 days prior to enrollment
* Sweat chloride concentration 50 mmol/L or greater while on elexacaftor/tezacaftor/ivacaftor

Exclusion Criteria:

* Prior lung transplant
* BMI \<18
* CF pulmonary exacerbation requiring hospitalization or intravenous antibiotics in the preceding 30 days
* Systemic corticosteroid or regular non-steroidal anti-inflammatory use in the preceding 30 days
* Chronic use of angiotensin receptor blockers or angiotensin converting enzyme inhibitors
* Concomitant use of medications known to interact with losartan, including aliskiren
* Chronic renal insufficiency (creatinine clearance \<45 ml/min)
* Pregnancy or lactation
* Inability or unwillingness to comply with approved contraceptive method during the study period (females of childbearing age)
* In the opinion of the investigator any severe or acute or chronic condition or laboratory abnormality that may increase the risk associated with trial participation or make the participant inappropriate for enrollment
* Participation in another interventional trial that, in the opinion of the investigator, has the potential to affect the primary outcome

Where it's running

• University of Kansas Medical Center
  Kansas City, Kansas, United States Recruiting

Study contacts

• Principal investigator: Charles Bengtson, MD, MSc — University of Kansas Medical Center
• Study coordinator: Heidi Hellwig
• Email: hhellwig@kumc.edu
• Phone: 9135886045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

  This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07342920

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.